Sandip S. Kshirsagar, Vaishali R. Shinde, Manjusha Nevase, Sayali Dudhal
2019-06-30
<p>Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. Such measurements ensure that clinical studies are testing our biological hypotheses and can help make the difficult decisions required to choose which drugs to stop developing or de-prioritise. In this review we discuss the intrinsic properties of biological sample based efficacy measurements and how these relate to their implementation in oncology drug development by way of points to consider and examples. In short use of biomarker data will help us make the best possible use of precious human samples and maximize the chances of success of the most promising therapeutic approaches.</p>
https://doi.org/10.5281/zenodo.3264828
oai:zenodo.org:3264828
Zenodo
https://zenodo.org/communities/iajpr
https://doi.org/10.5281/zenodo.3264827
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Biomarker, Diagnostic Biomarkers, Surrogate Markers.
REVIEW ON BIOMARKERS: TOOL FOR DIAGNOSIS OF A DISEASE AND DRUG DEVELOPMENT
info:eu-repo/semantics/article